Clinical Trial Update: Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating cilengitide in combination with sunitinib malate in adults with advanced solid tumors or glioblastoma multiforme has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Glioblastoma
• Glioblastoma
• Glioblastoma Multiforme
• Gliosarcoma

Drugs mentioned

• Sunitinib malate (sunitinib malate)
• cilengitide (cilengitide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 | Status: TERMINATED